TOCILIZUMAB-ANOH | B761420 | CELLTRION INC
Earliest legal licensure (12-year BPCIA floor)
The 12-year reference-product exclusivity is the non-carveable floor — the earliest FDA could license a biosimilar for any indication. Unverified estimate — derived from the earliest available approval record (Jan. 24, 2025), not an FDA-stated exclusivity date. Shown with lower confidence than a Purple Book value.
Full-label vs. best-skinny biosimilar entry
| Scenario | Date | Status | Controlling |
|---|---|---|---|
| Best-skinny entry (floor) | Jan. 24, 2037 | 10y 6mo remaining | 12-year RPE floor (non-carveable) |
| Full-label entry | Jan. 24, 2037 | 10y 6mo remaining | 12-year RPE floor |
Best-skinny equals full-label — no carveable orphan block runs past the licensure floor.
First-interchangeable exclusivity (§ 262(k)(6)): Jul. 24, 2026 — blocks other interchangeable designations only. It never gates plain biosimilar licensure and does not enter any entry-LOE above.
Marketing-entry ceiling (litigation risk)
Patents do not gate FDA licensure of a biosimilar — FDA licenses biosimilars (full or carved label) without adjudicating any patent. These are a practical marketing-entry ceiling resolved in the § 262(l) patent dance and ordinary litigation. A formulation/compound patent caps practical skinny entry via litigation (Regeneron v. Mylan); a method-of-use patent is carveable and gates nothing.
Latest formulation/compound patent 12023378(composition)· AI-discovered, not Purple-Book-listed · relevance 85/100. This caps practical skinny-label entry; it does not move the licensure floor above.
35 formulation/compound (cap skinny entry) · 3 method-of-use (carveable — gate nothing) · 12 device/diagnostic/manufacturing
| Patent | Class | Expiration | Source |
|---|---|---|---|
| 12421299 | Other | Sep. 18, 2045Active | Discovered |
| 12174184 | Other | Dec. 19, 2044Active | Discovered |
| 12023378 | Formulation/compound | Jun. 27, 2044Active | Discovered |
| 11976127 | Other | May. 2, 2044Active | Discovered |
| 11827717 | Formulation/compound | Nov. 23, 2043Active | Discovered |
| 11530275 | Formulation/compound | Dec. 15, 2042Active | Discovered |
| 11466087 | Formulation/compound | Oct. 6, 2042Active | Discovered |
| 11407794 | Formulation/compound | Aug. 4, 2042Active | Discovered |
| 11370838 | Other | Jun. 23, 2042Active | Discovered |
| 11285207 | Formulation/compound | Mar. 24, 2042Active | Discovered |
| 11242390 | Formulation/compound | Feb. 3, 2042Active | Discovered |
| 11221324 | Other | Jan. 6, 2042Active | Discovered |
| 11111311 | Formulation/compound | Sep. 2, 2041Active | Discovered |
| 10975168 | Other | Apr. 8, 2041Active | Discovered |
| 10844113 | Formulation/compound | Nov. 19, 2040Active | Discovered |
Showing 15 of 50 patents (latest expirations).
Approved Biosimilars
Disclaimer: Identifying an available carve-out is not a prediction that FDA will approve the particular carved label, nor that marketing it is free of infringement risk. For biologics, availability turns on exclusivities, not patents: FDA licenses a biosimilar (full or carved label) without adjudicating any patent, and patent disputes run through the § 262(l) patent dance and ordinary litigation, outside this availability view.
Top 50 of 787 AI-discovered patents by relevance.
No patent or exclusivity listings for this strength.